Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.

    Article  CAS  PubMed  Google Scholar 

  2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

    CAS  PubMed  Google Scholar 

  3. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

    CAS  PubMed  Google Scholar 

  4. Gentile M, Cutrona G, Mosca L, Matis S, Fabris S, Lionetti M et al. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. Am J Hematol 2014; 89: 743–750.

    Article  CAS  PubMed  Google Scholar 

  5. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008; 140: 537–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Morabito F, De Filippi R, Laurenti L, Zirlik K, Recchia K, Gentile M et al. The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood 2011; 118: 6353–6361.

    Article  CAS  PubMed  Google Scholar 

  7. Morabito F, Cutrona G, Gentile M, Matis S, Todoerti K, Colombo M et al. Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 2009; 146: 44–53.

    Article  CAS  PubMed  Google Scholar 

  8. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA et al. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011; 29: 4088–4095.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124: 49–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Ciardullo C et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013; 121: 1403–1412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109: 4679–4685.

    Article  CAS  PubMed  Google Scholar 

  12. Rai K. A critical analysis of staging in CLL. In: Gale R, Rai K (eds). Chronic Lymphocytic Leukemia: Recent Progress and Future Direction, vol. 59. Alan R Liss: New York, NY, USA, 1987, p 253..

  13. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.

    CAS  PubMed  Google Scholar 

  14. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kutsch N, Bahlo J, Byrd JC, Dohner H, Eichhorst B, Else M et al. The international Prognostic Index for patients with CLL (CLL-IPI): an international meta-analysis. J Clin Oncol 2015; 33: 7002 ASCO Annual Meeting Abstracts.

    Article  Google Scholar 

Download references

Acknowledgements

In addition to the listed Authors, the following investigators participated in this study as part of the Gruppo Italiano Studio Linfomi (GISL): Gianni Quintana, Divisione di Ematologia, Presidio Ospedaliero ‘A.Perrino’, Brindisi; Giovanni Bertoldero, Dipartimento di Oncologia, Ospedale Civile, Noale, Venezia; Paolo Di Tonno, Dipartimento di Ematologia, Venere, Bari; Maria Cristina Cox, Ematologia, A.O. Sant’Andrea, Università La Sapienza, Roma; Attilio Guarini, Unità di Ematologia e Trapianto di Cellule Staminali, Istituto di Oncologia ‘Giovanni Paolo II’, Bari; Antonio Abbadessa, U.O.C. di Oncoematologia Ospedale ‘S. Anna e S. Sebastiano’, Caserta; Francesco Iuliano, U.O.C. di Oncologia, Ospedale Giannettasio, Rossano Calabro, Cosenza; Omar Racchi, Ospedale Villa Scassi Sampierdarena, Genova; Mauro Spriano, Ematologia, A.O. San Martino, Genova; Felicetto Ferrara, Divisione di Ematologia, Ospedale Cardarelli, Napoli; Monica Crugnola, Ematologia, CTMO, Azienda Ospedaliera Universitaria di Parma; Alessandro Andriani, Dipartimento di Ematologia, Ospedale Nuovo Regina Margherita, Roma; Nicola Cascavilla, Unità di Ematologia e Trapianto di Cellule Staminali, IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo; Lucia Ciuffreda, Unità di Ematologia, Ospedale San Nicola Pellegrino, Trani; Graziella Pinotti, U.O. Oncologia Medica, Ospedale di Circolo Fondazione Macchi, Varese; Anna Pascarella, Unità Operativa di Ematologia, Ospedale dell'Angelo, Venezia-Mestre; Maria Grazia Lipari, Divisione di Ematologia, Ospedale Policlinico, Palermo, Francesco Merli, Unità Operativa di Ematologia, A.O.S. Maria Nuova, Reggio Emilia; Luca Baldini Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda-Maggiore Policlinico, Milano. This work was supported by funding from Associazione Italiana per la Ricerca sul Cancro (AIRC 5xmille grant 9980, IG10492 to MF and FM and IG10136 to AN). We thank AIL Cosenza-Fondazione Amelia Scorza’ onlus, Cosenza, Italy, and Brigida Gulino for precious secretarial assistance.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to M Gentile or F Morabito.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gentile, M., Shanafelt, T., Cutrona, G. et al. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia 30, 1440–1443 (2016). https://doi.org/10.1038/leu.2015.333

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.333

This article is cited by

Search

Quick links